A Prospective Observational Study About Adjuvant or Neoadjuvant Chemotherapy Related Adverse Effects in Premenopausal Breast Cancer Patients

• Conditions: Breast Cancer
• Interventions: Drug: GnRH analogue

• Registration Number: NCT03543059
• Lead Sponsor: Sun Yat-sen University

Brief Summary

Breast cancer is one of the most common malignant tumor in women. About 60% of breast cancer patients are still in premenopausal status at the time of diagnosis in China. It is a multicenter prospective observational study. We will collect basic information, medical history, chemotherapy-related adverse reactions, and the results of hormone, blood lipid, and bone density test before, during and after adjuvant or neoadjuvant chemotherapy. The aim of the study is to evaluate the effect of chemotherapy on ovarian function and fertility and the protective effect of GnRHa. In addition, the collected information of the subjects are analyzed to provide suggestions for the relevant prevention strategy.

Detailed Description

Breast cancer is one of the most common malignant tumor in women, and it occurs at a younger median age in Chinese women than in western white women. About 60% of breast cancer patients are still in premenopausal status at the time of diagnosis in China. Chemotherapy is one of the important treatments for breast cancer, but it brings a series of adverse effects. It is a multicenter prospective observational study. The premenopausal breast cancer women patients who are planning adjuvant or neoadjuvant chemotherapy are enrolled in the study after signing the informed consent form and passing the screening. We collect their basic information, medical history, chemotherapy-related adverse reactions, and the results of hormone, blood lipid, and bone density test before, during and after chemotherapy. The aim of the study is to evaluate the effect of adjuvant or neoadjuvant chemotherapy on ovarian function and fertility and the protective effect of GnRHa by investigating the menopausal symptoms, pregnancy, menstruation condition, hormone levels, blood lipid, bone density, and the usage of GnRHa in the premenopausal women with breast cancer. In addition, the collected information of the subjects are analyzed to provide suggestions for the relevant prevention strategy.

Study Timeline

• Status Verified: 2018-05
• Study First Submitted: 2018-05-21
• Study First Submitted QC: 2018-05-21
• Last Update Submitted: 2018-05-21
• Study First Posted: 2018-06-01
• Last Update Posted: 2018-06-01
• Study Start: 2018-06-15
• Primary Completion: 2021-06-15
• Study Completion: 2023-06-15

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 2000

Inclusion Criteria

1. Informed consent form has been signed.
2. Breast cancer patients whose age is ≥ 18 years old and have been diagnosed by histological examination.
3. Plan for adjuvant or neoadjuvant chemotherapy

Exclusion Criteria

1. Postmenopausal women who are defined by any of the following:

   • Previous bilateral oophorectomy;
   • Age ≥ 60 years old;
   • Age <60 years old, menopause at least 12 months, and follicle stimulating hormone [FSH] and estradiol levels in the postmenopausal range.

2. Those who have already received adjuvant or neoadjuvant chemotherapy.

3. Those who have chemotherapy contraindications.

4. Those who have any mental condition that prevents the understanding of the contents of this study and can't provide the complete information required.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
exposure group	GnRH analogue	exposed to some factors

Primary Outcome Measures

Name	Time	Method
Pregnancy outcome	5 years	The number of patients reporting pregnancy and attempting pregnancy

Secondary Outcome Measures

Name	Time	Method
Rate of ovarian failure	2 years	Amenorrhea for 6 months and postmenopausal FSH levels at 24 months (amenorrhea and postmenopausal hormone levels

Trial Locations

Locations (1)

Shusen Wang; 🇨🇳 Guangzhou, Guangdong, China